HQY vs ZBH
HealthEquity vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | HQY | ZBH |
|---|
| AI Score |
64
|
67
|
| Price |
$106.83
|
$97.77
|
| P/E Ratio |
38.75×
|
23.38×
|
| ROE |
10.2%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.7%
|
69.9%
|
| Debt / Equity |
0.48×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
65.8
|
58.9
|
| Beta |
0.21
|
0.462
|
| Expected Upside |
+1.0%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for HQY versus ZBH.
ZBH leads by 3 points.
ZBH scores 67/100 (Buy) versus HQY at 64/100 (Buy).
HQY Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 15.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.3% signals elevated volatility — Risk
ZBH Committee View
80% agreement
5 analysts
The primary driver is price-to-book of 1.4x is a discount to asset value. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.